The estimated Net Worth of Juan Vera is at least $12.2 Milione dollars as of 16 March 2021. Dr Vera owns over 571,428 units of Marker Therapeutics stock worth over $7,129,274 and over the last 6 years he sold MRKR stock worth over $5,063,825.
Dr has made over 5 trades of the Marker Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 571,428 units of MRKR stock worth $999,999 on 16 March 2021.
The largest trade he's ever made was buying 571,428 units of Marker Therapeutics stock on 16 March 2021 worth over $999,999. On average, Dr trades about 43,654 units every 2 days since 2018. As of 16 March 2021 he still owns at least 2,564,487 units of Marker Therapeutics stock.
You can see the complete history of Dr Vera stock trades at the bottom of the page.
Dr. Juan F. Vera M.D. is the Co-Founder, COO, Chief Scientific Officer & Director at Marker Therapeutics.
Dr D is 41, he's been the Co-Founder, COO e Chief Scientific Officer & Director of Marker Therapeutics since . There are 4 older and no younger executives at Marker Therapeutics. The oldest executive at Marker Therapeutics, Inc. is Michael J. Loiacono, 55, who is the Chief Accounting Officer, Treasurer & Sec..
Juan's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Marker Therapeutics have traded over $0 worth of Marker Therapeutics stock and bought 60,748,562 units worth $106,570,272 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Marker Therapeutics executives and independent directors trade stock every 38 days with the average trade being worth of $9,934,177. The most recent stock trade was executed by Frederick Gerald Wasserman on 18 May 2021, trading 10,000 units of MRKR stock currently worth $24,100.
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics executives and other stock owners filed with the SEC include: